Literature DB >> 21135880

Pediatric rheumatology: JIA, treatment and possible risk of malignancies.

Nicolino Ruperto, Alberto Martini.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21135880     DOI: 10.1038/nrrheum.2010.199

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  8 in total

1.  Should the Food and Drug Administration warning of malignancy in children receiving tumor necrosis factor alpha blockers change the way we treat children with juvenile idiopathic arthritis?

Authors:  Thomas J A Lehman
Journal:  Arthritis Rheum       Date:  2010-08

Review 2.  Juvenile idiopathic arthritis: state of the art and future perspectives.

Authors:  Alberto Martini; Daniel J Lovell
Journal:  Ann Rheum Dis       Date:  2010-06-04       Impact factor: 19.103

3.  Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration.

Authors:  Peter Diak; Jeffrey Siegel; Lois La Grenade; Lauren Choi; Steven Lemery; Ann McMahon
Journal:  Arthritis Rheum       Date:  2010-08

4.  Malignancies in children who initially present with rheumatic complaints.

Authors:  D A Cabral; L B Tucker
Journal:  J Pediatr       Date:  1999-01       Impact factor: 4.406

5.  Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study.

Authors:  J F Simard; M Neovius; S Hagelberg; J Askling
Journal:  Arthritis Rheum       Date:  2010-12

Review 6.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.

Authors:  Josef S Smolen; Robert Landewé; Ferdinand C Breedveld; Maxime Dougados; Paul Emery; Cecile Gaujoux-Viala; Simone Gorter; Rachel Knevel; Jackie Nam; Monika Schoels; Daniel Aletaha; Maya Buch; Laure Gossec; Tom Huizinga; Johannes W J W Bijlsma; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Cem Gabay; Juan Gomez-Reino; Marios Kouloumas; Tore K Kvien; Emilio Martin-Mola; Iain McInnes; Karel Pavelka; Piet van Riel; Marieke Scholte; David L Scott; Tuulikki Sokka; Guido Valesini; Ronald van Vollenhoven; Kevin L Winthrop; John Wong; Angela Zink; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-05-05       Impact factor: 19.103

Review 7.  International research networks in pediatric rheumatology: the PRINTO perspective.

Authors:  Nicolino Ruperto; Alberto Martini
Journal:  Curr Opin Rheumatol       Date:  2004-09       Impact factor: 5.006

8.  Methotrexate therapy in juvenile rheumatoid arthritis: a retrospective study.

Authors:  H Truckenbrodt; R Häfner
Journal:  Arthritis Rheum       Date:  1986-06
  8 in total
  4 in total

1.  High Levels of Decisional Conflict and Decision Regret When Making Decisions About Biologics.

Authors:  Ellen A Lipstein; Daniel J Lovell; Lee A Denson; Sandra C Kim; Charles Spencer; Richard F Ittenbach; Maria T Britto
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-12       Impact factor: 2.839

Review 2.  Advances from clinical trials in juvenile idiopathic arthritis.

Authors:  Daniel J Lovell; Nicola Ruperto; Edward H Giannini; Alberto Martini
Journal:  Nat Rev Rheumatol       Date:  2013-07-09       Impact factor: 20.543

Review 3.  Juvenile idiopathic arthritis.

Authors:  Alberto Martini; Daniel J Lovell; Salvatore Albani; Hermine I Brunner; Kimme L Hyrich; Susan D Thompson; Nicolino Ruperto
Journal:  Nat Rev Dis Primers       Date:  2022-01-27       Impact factor: 65.038

4.  Current medical treatments for juvenile idiopathic arthritis.

Authors:  Nicolino Ruperto; Alberto Martini
Journal:  Front Pharmacol       Date:  2011-10-10       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.